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Two  main  molecular  targets  of 
∆9-  tetrahydrocannabinol  (∆9-THC),  the 
psychoactive principle of Cannabis sativa, 
are type-1 (CB1) and type-2 (CB2) cannabi-
noid receptors (Howlett et al., 2010). In the 
past few years many endogenous agonists of 
CB receptors have been characterized, and 
are collectively called “endocannabinoids” 
(Maccarrone et al., 2010). They are mainly 
amides and esters of long-chain polyunsat-
urated fatty acids isolated from brain and 
peripheral tissues and, although structurally 
different  from  plant  cannabinoids,  share 
critical  pharmacophores  with  ∆9-THC 
(Pertwee, 2010). Two arachidonate deriva-
tives, N-arachidonoylethanolamine (anan-
damide, AEA) and 2-arachidonoylglycerol 
(2-AG), were shown to mimic ∆9-THC by 
functionally activating CB receptors, and 
these  are  the  endocannabinoids  whose 
biological activity has been best character-
ized to date (Di Marzo, 2009; Maccarrone 
et al., 2010).
CB1 receptor is the most abundant G 
protein-coupled receptor (GPCR) in the 
brain (Howlett et al., 2010). Together with 
its endogenous agonists (AEA, 2-AG, and 
other congeners), CB1 belongs to an ancient 
neurosignaling system that plays important 
control functions within the central nerv-
ous  system  (Katona  and  Freund,  2008). 
Alterations  in  this  so-called  “endocan-
nabinoid  system”  have  been  extensively 
investigated in a wide range of neurode-
generative and neuroinflammatory disor-
ders, spanning from Alzheimer’s disease, 
Parkinson’s disease and Huntington’s dis-
ease, to amyotrophic lateral sclerosis and 
multiple sclerosis (Bisogno and Di Marzo, 
2010).  For  this  reason,  research  on  the 
therapeutic  potential  of  drugs  modulat-
ing  the  endocannabinoid  system  is  very 
intense (Di Marzo, 2009). More recently, 
it has become evident the involvement of 
membrane  lipids,  especially  cholesterol 
and glycosphingolipids, in regulating the 
function of GPCRs like β2-adrenergic and 
serotonin1A receptors, as well as of several 
other membrane-associated proteins like 
caveolins (Pontier et al., 2008; Prinetti et al., 
2009; Paila et al., 2010; Shrivastava et al., 
2010). Also a role for membrane choles-
terol in the functional regulation of CB1 
has been well-documented (for an updated 
review see Dainese et al., 2010). Acute cho-
lesterol depletion by methyl-β-cyclodextrin 
has been shown to double CB1-dependent 
signaling via adenylyl cyclase and mitogen-
activated  protein  kinases  in  neuronal 
cells (Bari et al., 2005a,b). Conversely, it 
has been reported that in the same cells 
CB1-dependent  binding  and  signaling 
was  significantly  reduced  by  cholesterol 
enrichment  (Bari  et  al.,  2005a,b,  2006). 
Notably,  the  CB2  receptor  that  is  struc-
turally and functionally related to CB1 is 
completely insensitive to the modulation of 
membrane cholesterol content (Bari et al., 
2006), and does not reside in cholesterol-
rich  microdomains  like  lipid  rafts  (Bari 
et al., 2006; Rimmerman et al., 2008). As 
yet, the molecular basis for the different 
response of these two receptor subtypes 
to cholesterol remains unclear, although 
its impact on the therapeutic exploitation 
of CB1-dependent endocannabinoid sign-
aling versus that dependent on CB2 could 
be immense.
Here, I would like to comment that sub-
tle, yet specific, differences might underpin 
the differential sensitivity of CB1 and CB2 
to membrane cholesterol, possibly explain-
ing  the  apparent  redundancy  of  having 
two largely overlapping receptor subtypes 
that are activated by similar compounds 
(endocannabinoids)  and  trigger  similar 
transduction pathways: (i) inhibition of 
adenylyl cyclase, (ii) regulation of ionic 
currents (e.g., inhibition of voltage-gated 
L, N, and P/Q-type Ca2+ channels, and acti-
vation of K+ channels), and (iii) activation 
of focal adhesion kinase, mitogen-activated 
protein kinase, and cytosolic phospholi-
pase A2 (Di Marzo, 2009; Maccarrone et al., 
2010).
In general, cholesterol may act on the 
conformation  of  a  membrane  recep-
tor  by  indirectly  altering  the  physico-
chemical properties of the bilayer, or by 
directly   interacting with the receptor itself. 
Although a unique conserved structural 
determinant for protein interaction with 
cholesterol has not yet been identified, a 
well-known motif is the cholesterol inter-
action/recognition amino acid sequence 
consensus [L/V-X(1–5)-Y-X(1–5)-R/K], named 
CRAC (Epand, 2006). This motif has been 
demonstrated  in  caveolin-1,  peripheral-
type  benzodiazepine  receptor  (Li  and 
Papadopoulos, 1998; Jamin et al., 2005), 
and in other proteins targeted to lipid rafts 
(Xie et al., 2010). Interestingly, by sequence 
alignment of human CB1 and CB2 we have 
recently identified the presence of CRAC in 
the last 11 amino acids of the transmem-
brane helix 7 of both CB1 and CB2 (Oddi 
et al., 2011). In particular, we found that in 
the highly conserved CRAC region (82% 
amino acid identity), CB1 differs from CB2 
for one residue only: lysine 402 of CB1 
(Figure 1) corresponds to glycine 304 in 
CB2 (Oddi et al., 2011). We also found that 
the CB1(K402G) mutant where the CRAC 
sequence of CB1 was converted into that 
of CB2 had a reduced propensity to reside 
in cholesterol-rich membrane regions, and 
lost its sensitivity to membrane cholesterol 
enrichment (Oddi et al., 2011). Therefore, 
one residue in complex proteins like GPCRs 
can be enough to direct their interaction 
with membrane lipids, thus affecting signal 
transduction thereof.
Different non-mutually exclusive mech-
anisms could be proposed to explain the 
differential sensitivity of CB1 and CB2 to 
membrane cholesterol: (i) compartmentali-
zation in cholesterol-rich microdomains; 
(ii) caveolar endocytosis; (iii) cholesterol-
dependent  receptor  dimerization;  (iv) 
hydrophobic  mismatch;  (v)  modulation 
of the rate of endocannabinoid movement 
within the membrane (Dainese et al., 2010). 
Additionally, it is possible that the differ-
ent effect of membrane cholesterol on CB1 
and CB2 is due to subtle differences in the 
domain(s)  that  interact(s)  with  the  sur-
rounding (non-annular) lipids, by   analogy Frontiers in Psychology  |  Membrane Physiology and Biophysics    October 2010  | Volume 1  | Article 140  |  2
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lipids. As  a  consequence,  the  membrane 
environment might play a role in receptor-
dependent signaling, with a potential impact 
on several neurotransmission pathways, as 
well as several neurodegenerative/neuroin-
flammatory diseases where CB1 is known 
to play a role. More in general, it should 
be recalled that CB1-dependent signaling 
impacts fundamental processes as differ-
ent as immune response, energy homeos-
tasis, reproduction, and skin differentiation 
(Di Marzo, 2009; Maccarrone et al., 2010), 
thus it can be anticipated that cholesterol-
dependent regulation of CB1 can have a 
physiological  relevance  well-beyond  the 
central nervous system.
In conclusion, membrane environment 
seems to be critical for the regulation of sig-
nal transduction pathways triggered by G 
with  other  GPCRs  (Paila  et  al.,  2010). 
Additionally,  other  lipid-interacting  resi-
dues might direct the interaction of CB1 
with the surrounding membrane lipids, e.g., 
cysteine 415 in its C-terminal (Figure 1), 
that could be the target of palmitoylation 
(Dainese  et  al.,  2010).  The  latter  revers-
ible post-translational modification can be 
used by cells to regulate CB1 targeting to 
cholesterol-rich subdomains of the mem-
brane, thus influencing its interaction with 
coupled G proteins.
I believe that the comparison between 
CB1 and CB2 might represent an interesting 
paradigm that goes well-beyond endocan-
nabinoid signaling. In fact, the modulation 
of CB1 by cholesterol might disclose a novel 
ligand–receptor interaction, where a third 
player  comes  into  the  game:  membrane 
Figure 1 | Three-dimensional model of CB1, based on sequence alignment with visual rhodopsin in 
the inactivated state (PDB code: 1F88). The model was obtained using the protein structure homology-
modeling server SWISS-MODEL, integrated in the Deep-View program (Dainese et al., 2010). The three 
residues (V392, Y397 , K402) that form the CRAC sequence are represented as yellow spheres, sized to the 
Van der Waals radii; these residues belong to the transmembrane helix 7 of CB1. Recently, we have 
generated a mutant where a lysine residue (K402) was substituted by glycine, thus converting the CRAC 
sequence of CB1 into that of CB2 (Oddi et al., 2011). Additionally, the C-terminal component of CB1, i.e., the 
intracellular juxtamembrane α-helix 8, contains a cysteine residue (C415, in green) that could be 
constitutively palmitoylated. See text for details. The model was kindly provided by Dr. Enrico Dainese 
(University of Teramo, Italy).
protein-coupled receptors like CB1. Despite 
the three-dimensional complexity of these 
proteins, we learn from the comparison of 
CB1 with CB2 that just one amino acid resi-
due can direct receptor functioning, calling 
for attention on the plasma membrane as 
a key-player in ligand recognition on the 
cell surface.
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